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Abstract
Numerous studies have examined low penetrance susceptibility
polymorphisms in candidate genes, with some reporting significant
findings. However, for the most part these associations could not
be replicated in subsequent studies, suggesting that the original
observations were due to chance. The failure to identify meaningful
common genetic variation in relation to breast cancer should give
us pause for thought and make us reconsider our current research
strategies. The most recent directions of pooling samples to
increase statistical power and pursuing whole genome screens
may overcome some obstacles while also creating new challenges.
Future studies should perhaps also consider alternative designs
such as using surrogate (preferably continuous) markers of breast
cancer, focusing on high-risk populations, and defining patho-
logically distinct outcomes.
Introduction
There is considerable evidence that genetics plays a role in
breast cancer. Women with a family history of breast cancer
are at a near twofold increased risk for breast cancer. Identifi-
cation of highly penetrant genes has supported the notion
that breast cancer is a genetic disease. However, these
genes (e.g. BRCA1 and BRCA2) account for a very small
percentage of breast cancers in the population [1]. The
common disease-common variant hypothesis has been one
of the overarching suppositions driving many of the breast
cancer association studies [2,3]. This hypothesis suggests
that the risk attributable to genetics for common diseases will
come from alleles that are not under severe negative
selection and that are in the population at a relatively high
frequency. This hypothesis is appealing from a public health
perspective because common variants will have the greatest
impact at the population level.
The sequencing of the human genome and discovery of
millions of single nucleotide polymorphisms (SNPs) [4]
provided the opportunity to characterize human genetic
variation and its impact on breast cancer systematically.
Numerous  studies have examined low penetrance
susceptibility polymorphisms in candidate genes, with some
reporting significant findings. However, for the most part these
associations could not be replicated in subsequent studies,
suggesting that the original observations were due to chance
[5]. In a pooled analysis of 46 association studies examining
polymorphisms in 18 different genes, only three poly-
morphisms were significantly associated with breast cancer
[5]. Despite considerable efforts made during the past few
years to study genetic variation and breast cancer, there has
been little success in identifying important contributions to
breast cancer. The lack of robust and consistent findings from
single SNP association studies led to the explosion of
haplotype studies, which promised to examine more compre-
hensively the association between common genetic variation
in candidate genes and risk for disease. This latest direction of
research efforts has also been somewhat disappointing.
Models of genetics and breast cancer risk
It is becoming increasing clear that our working hypotheses
and approaches may have been too simplistic for a complex
and multifactorial disease such as breast cancer. A more
recent model of risk suggests that a large fraction of the
burden of breast cancer risk may be concentrated in a
relatively small proportion of the female population [6,7]. If
this theory proves correct, then it could have profound
implications for screening, risk prediction and, ultimately,
chemoprevention. However, additional evidence to support
this model is needed. Family history of breast cancer is a fairly
common and robust risk factor for breast cancer, challenging
the supposition that the contribution of genetics to risk is
limited to only a small fraction of the population.
The prevailing polygenic model of breast cancer risk
suggests that a moderate number of genes, each conferring a
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small amount of risk alone (relative risk 1.3-1.5), together
would combine multiplicatively, resulting in modest suscepti-
bility to breast cancer [7]. According to this model, more than
100 genes may contribute to breast cancer susceptibility.
These genes could have either common or rare variants.
Women carrying more variant alleles would be at greater risk
than those carrying fewer. Recently, a rare variant (about
1.1% in healthy populations) identified in the Chk2 gene has
been reported to confer a 1.5-fold to 2.0-fold increase in
breast cancer risk in individuals that carry this allele [8,9]. The
CHEK2*1100delC allele, which abolishes kinase activity of
the protein, lends support to the polygenic model [8,9]. To
date, this is the first polymorphism to be successfully con-
firmed with strong statistical power. Additional confirmation
of these results and identification of additional genes
conferring modest risk will lend further support to this model.
Even in the best case scenario, in which researchers are able
to identify a set of 100 genes that each modestly contribute
to breast cancer risk, it is unclear what the public health utility
of testing in the population would be. Perhaps, the greatest
advancement would come from the potential identification of
new pathways that contribute to breast cancer that could
ultimately be targets for screening, chemoprevention, or
treatment.
Limitations of current studies
There are several potential reasons for a lack of consistent
findings between SNPs and breast cancer. First, breast
cancer is a heterogeneous disease, but most analyses treat it
as one. Just as nongenetic breast cancer risk factors may be
differentially associated with specific tumor types [10], so
might genetic factors. Second, most association studies to
date have utilized a candidate gene approach, in which we
are limited by our biologic knowledge. The genome contains
an estimated 20,000-25,000 genes, many of which play
redundant roles or are components of pathways. Thus, a
functional polymorphism in one gene may be compensated
for by a functionally similar or downstream gene. Third, by
definition, low penetrance genes do not cause disease - they
make individuals more susceptible. The same landmark study
that provided statistical evidence that breast cancer was
heritable also concluded that environmental factors and
somatic changes are the major contributors to breast cancers
occurring in the population [11]. Without considering other
factors that influence this susceptibility, whether they be
dietary factors, reproductive factors, or somatic alterations, it
will be very difficult to detect an association in our traditional
population studies.
One solution to overcome some of these challenges is to
increase statistical power. Comprehensive efforts, such as
the HapMap project to identify variation and determine
linkage disequilibrium patterns, and advances in genotyping
technology are providing the necessary reagents to perform
adequately powered large-scale association studies. The
Breast and Prostate Cancer Cohort Consortium (BPC3) is
pooling resources from nine cohort studies to include more
than 5000 cases of breast cancer to address the role of
common variants with respect to breast cancer [12]. That
study should have sufficient power to detect small to
moderate effects and will examine gene-gene and gene-
environment interactions. The limited success of the candi-
date gene approach, together with technologic advances in
the development of whole genome scans, has opened the
door for less hypothesis driven research. Because many of
the identified millions of SNPs are perfectly correlated with
one another, one tagging SNP can serve as a proxy for other
variants. It is believed that a few hundred thousand well
selected SNPs can capture the majority of common genetic
variation in the genome [13]. Whole genome scans can now
be performed, and will allow researchers to conduct genome-
wide association studies with no a priori assumptions about
loci [14]. The most evident concern regarding the genome
scans is that they will lead to false-positive results. Therefore,
these studies also have foreseeable challenges in
determining appropriate sample sizes, statistical issues of
data analysis and accounting for multiple testing, and
reproducibility in other data sets.
Conclusion
The failure to identify meaningful common genetic variation in
relation to breast cancer should give us pause for thought and
make us reconsider our current research strategies. The most
recent directions of increasing sample size through pooling
and pursuing whole genome screens may overcome some of
the obstacles. However, both are still directed at detecting
common genetic variation and may miss meaningful risk alleles
occurring at less than 5%. Use of a highly heritable,
continuous outcome measure such as mammographic density
may be an alternative and powerful tool for identifying genes
associated with breast cancer. Based on twin studies, the
heritability of breast cancer has been estimated to be 27%
[11]. In contrast, mammographic density - considered by
some to be a surrogate marker of breast cancer risk - is a
highly heritable trait, more so than breast cancer. The
correlation between mammographic density in monozygotic
twins ranges from 0.61 to 0.67 [15], suggesting that the
majority of variation in mammographic density is explained by
genetic factors. Future studies should perhaps also consider
alternative designs such as using surrogate (preferably
continuous) markers of breast cancer, focusing on high-risk
populations, and defining pathologically distinct outcomes.
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